IN2013CN01129A - - Google Patents

Download PDF

Info

Publication number
IN2013CN01129A
IN2013CN01129A IN1129CHN2013A IN2013CN01129A IN 2013CN01129 A IN2013CN01129 A IN 2013CN01129A IN 1129CHN2013 A IN1129CHN2013 A IN 1129CHN2013A IN 2013CN01129 A IN2013CN01129 A IN 2013CN01129A
Authority
IN
India
Prior art keywords
determining
level
colorectal cancer
diagnosing
detecting
Prior art date
Application number
Other languages
English (en)
Inventor
Leah Jane Cosgrave
Bruce Tabor
Tony W Burgess
Edouard Collins Nice
Original Assignee
Commw Scient Ind Res Org
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010903140A external-priority patent/AU2010903140A0/en
Application filed by Commw Scient Ind Res Org filed Critical Commw Scient Ind Res Org
Publication of IN2013CN01129A publication Critical patent/IN2013CN01129A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57419Specifically defined cancers of colon
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
IN1129CHN2013 2010-07-14 2011-07-14 IN2013CN01129A (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2010903140A AU2010903140A0 (en) 2010-07-14 Diagnostic for colorectal cancer
PCT/AU2011/000895 WO2012006681A1 (en) 2010-07-14 2011-07-14 Diagnostic for colorectal cancer

Publications (1)

Publication Number Publication Date
IN2013CN01129A true IN2013CN01129A (xx) 2015-07-31

Family

ID=45468816

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1129CHN2013 IN2013CN01129A (xx) 2010-07-14 2011-07-14

Country Status (13)

Country Link
US (2) US20130345322A1 (xx)
EP (2) EP2829881B1 (xx)
JP (1) JP6061344B2 (xx)
CN (2) CN105755112B (xx)
AU (1) AU2011279555B2 (xx)
BR (1) BR112013000745B1 (xx)
DK (1) DK2829881T3 (xx)
ES (1) ES2653646T3 (xx)
IN (1) IN2013CN01129A (xx)
NO (1) NO2829881T3 (xx)
PT (1) PT2829881T (xx)
RU (1) RU2013103995A (xx)
WO (1) WO2012006681A1 (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013103995A (ru) 2010-07-14 2014-08-20 Коммонуэл Сайентифик энд Индастриз Рисерч Организейшн Диагностика колоректального рака
US9141756B1 (en) 2010-07-20 2015-09-22 University Of Southern California Multi-scale complex systems transdisciplinary analysis of response to therapy
AU2012212075A1 (en) 2011-02-02 2013-07-18 Amgen Inc. Methods and compositons relating to inhibition of IGF-1R
PT2883057T (pt) 2012-08-09 2019-03-06 Univ Toulouse 3 Paul Sabatier Diagnóstico de insuficiência cardíaca
GB201218341D0 (en) * 2012-10-12 2012-11-28 Orign Sciences Ltd Diagnostic method
US20170176441A1 (en) * 2014-03-28 2017-06-22 Applied Proteomics, Inc. Protein biomarker profiles for detecting colorectal tumors
EA035674B1 (ru) * 2014-07-18 2020-07-24 Санофи Способ определения того, является ли пациент, предположительно страдающий от рака, кандидатом для терапии афлиберцептом
CN106191215B (zh) * 2015-04-29 2020-03-24 中国科学院上海生命科学研究院 肌肉萎缩相关的蛋白质分子标记Dkk-3的筛选及其应用
US10877024B2 (en) * 2015-05-12 2020-12-29 Superlab Far East Limited Methods of determining interferon having direct inhibitory effects on tumors and uses thereof
CN105219844B (zh) * 2015-06-08 2018-12-14 华夏京都医疗投资管理有限公司 一种筛查十一种疾病的基因标志物组合、试剂盒以及疾病风险预测模型
CN105021828B (zh) * 2015-07-20 2017-07-28 上海交通大学医学院附属新华医院 通过检测三期结直肠肿瘤患者血清预测肿瘤患者预后
CN105567846A (zh) * 2016-02-14 2016-05-11 上海交通大学医学院附属仁济医院 检测粪便中细菌dna的试剂盒及其在大肠癌诊断中的应用
JP6984862B2 (ja) * 2017-03-15 2021-12-22 国立大学法人金沢大学 血中ケモカインをマーカーとして用いた大腸癌の検出
CN107164535A (zh) * 2017-07-07 2017-09-15 沈阳宁沪科技有限公司 一种无创高通量甲基化结肠癌诊断、研究和治疗方法
CN110540588B (zh) * 2018-05-28 2022-08-23 香港中文大学 一种基于肿瘤干细胞标志物EpCAM的抗原表位多肽及其应用
CN108957014A (zh) * 2018-09-27 2018-12-07 郑州大学第附属医院 结直肠癌血清标志物、表达评估方法、试剂盒及应用
JP2022505676A (ja) * 2018-10-23 2022-01-14 ブラックソーン セラピューティクス インコーポレイテッド 患者のスクリーニング、診断、及び層別化のためのシステム及び方法
JP7442967B2 (ja) 2018-11-30 2024-03-05 トヨタ紡織株式会社 センターブラケット
CN109504778B (zh) * 2019-01-11 2021-11-09 复旦大学附属中山医院 一种基于表观修饰的5hmC多分子标志物及结直肠癌早期诊断模型
JP2022522803A (ja) * 2019-03-01 2022-04-20 アドバンスド マーカー ディスカバリー エセ. エレ. 結腸直腸癌及び/又はその前癌段階の診断用タンパク質シグネチャー
JP7032764B2 (ja) * 2019-04-03 2022-03-09 京都府公立大学法人 大腸がんの検出方法
JP7300660B2 (ja) * 2019-04-03 2023-06-30 京都府公立大学法人 大腸がんの検出方法
EP3835789A1 (en) 2019-12-13 2021-06-16 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Biomarker panel for diagnosing colorectal cancer
WO2022130597A1 (ja) * 2020-12-18 2022-06-23 国立大学法人東北大学 推定装置、推定方法、推定プログラム、生成装置、及び、推定システム
CN117355748A (zh) * 2021-04-20 2024-01-05 视觉技术生物有限公司 结直肠癌的生物标志物
CA3228665A1 (en) * 2021-08-11 2023-02-16 Trevor Lockett Method of detecting adenoma
WO2023128419A1 (ko) * 2021-12-31 2023-07-06 주식회사 이노제닉스 대장암 및 대장 용종 또는 진행 선종의 선별 방법 및 그 응용
WO2023128429A1 (ko) * 2021-12-31 2023-07-06 주식회사 이노제닉스 대장암 및 진행 선종의 선별 검사 방법 및 그 응용
CN114594259B (zh) * 2022-04-22 2022-09-13 北京易科拜德科技有限公司 一种新型的用于结直肠癌预后预测和诊断的模型及其应用
PL441319A1 (pl) * 2022-05-31 2023-12-04 Uniwersytet Medyczny Im. Piastów Śląskich We Wrocławiu Zestaw biomarkerów białkowych i sposób diagnostyki raka jelita grubego in vitro

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US20040157278A1 (en) * 2002-12-13 2004-08-12 Bayer Corporation Detection methods using TIMP 1
US20050014165A1 (en) * 2003-07-18 2005-01-20 California Pacific Medical Center Biomarker panel for colorectal cancer
CA2537818A1 (en) * 2003-09-15 2005-03-31 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases
BRPI0401830A (pt) 2004-05-25 2006-01-17 Bentonit Uniao Nordeste Sa Processo de produção de pós granulados secos
CA2655997A1 (en) * 2006-06-30 2008-01-10 Schering Corporation Igfbp2 biomarker
WO2008073660A1 (en) 2006-11-09 2008-06-19 University Of Washington Molecules and methods for treatment and detection of cancer
EP2094719A4 (en) * 2006-12-19 2010-01-06 Genego Inc NEW PROCEDURES FOR THE FUNCTIONAL ANALYSIS OF EXPERIMENTAL HIGH-PERFORMANCE DATA AND IDENTIFIED GENDER GROUPS THEREOF
US20080221056A1 (en) 2007-02-12 2008-09-11 Johns Hopkins University Early Detection and Prognosis of Colon Cancers
RU2489720C2 (ru) * 2007-02-27 2013-08-10 Сентоклон Интернэшнл Аб Мультиплексная детекция опухолевых клеток с использованием панели агентов, связывающихся с внеклеточными маркерами
WO2008116178A2 (en) * 2007-03-21 2008-09-25 Vanderbilt University Systems and methods for diagnosis and prognosis of colorectal cancer
CN101680898A (zh) * 2007-05-10 2010-03-24 霍夫曼-拉罗奇有限公司 Timp-1作为结肠直肠癌标志的用途
WO2008144345A2 (en) * 2007-05-17 2008-11-27 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
CN101971033A (zh) * 2007-06-04 2011-02-09 戴诺普雷克斯公司 用于结直肠癌的生物标志物组合
US20090017463A1 (en) * 2007-07-10 2009-01-15 Vanderbilt University Methods for predicting prostate cancer recurrence
EP2271775A4 (en) * 2008-04-08 2011-09-07 Nuclea Biomarkers Llc BIOMARKERGROUP FOR PREDICTING THE REPRESENTATION OF COLORECTAL CARCINOMA
US20100111969A1 (en) * 2008-10-31 2010-05-06 Apogenix Gmbh Il-4 receptor and il-13 as prognostic markers for colon and pancreas tumors
US20100173024A1 (en) * 2008-12-01 2010-07-08 LifeSpan Extension, LLC Methods and compositions for altering health, wellbeing, and lifespan
EP2370813A4 (en) * 2008-12-04 2012-05-23 Univ California MATERIALS AND METHODS FOR DIAGNOSIS AND PROGNOSIS OF PROSTATE CANCER
US9354233B2 (en) * 2009-02-20 2016-05-31 The Regents Of The University Of California A+ biomarker assays
US20110177525A1 (en) * 2010-01-19 2011-07-21 Predictive Biosciences, Inc. Antibodies and methods of diagnosing diseases
RU2013103995A (ru) * 2010-07-14 2014-08-20 Коммонуэл Сайентифик энд Индастриз Рисерч Организейшн Диагностика колоректального рака

Also Published As

Publication number Publication date
EP2829881A3 (en) 2015-05-13
RU2013103995A (ru) 2014-08-20
JP2013533977A (ja) 2013-08-29
NO2829881T3 (xx) 2018-01-20
AU2011279555A1 (en) 2013-01-31
CN103140760A (zh) 2013-06-05
EP2593795A1 (en) 2013-05-22
PT2829881T (pt) 2017-11-29
CN105755112B (zh) 2019-06-07
US10877039B2 (en) 2020-12-29
ES2653646T3 (es) 2018-02-08
EP2829881B1 (en) 2017-08-23
US20130345322A1 (en) 2013-12-26
BR112013000745A2 (pt) 2016-05-24
BR112013000745B1 (pt) 2021-02-02
WO2012006681A1 (en) 2012-01-19
JP6061344B2 (ja) 2017-01-18
AU2011279555B2 (en) 2016-10-20
CN103140760B (zh) 2016-01-27
US20170205414A1 (en) 2017-07-20
EP2829881A2 (en) 2015-01-28
EP2593795A4 (en) 2014-01-22
CN105755112A (zh) 2016-07-13
DK2829881T3 (en) 2017-12-04

Similar Documents

Publication Publication Date Title
IN2013CN01129A (xx)
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
WO2013093635A3 (en) Plasma micrornas for the detection of early colorectal cancer
WO2009037572A3 (en) Biomarker combinations for colorectal cancer
MX340453B (es) Biomarcadores para cancer de pulmon.
WO2012021887A3 (en) Biomarkers for the early detection of breast cancer
MX2013001042A (es) Biomarcadores de cancer pancreatico y usos de los mismos.
NZ593514A (en) p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer
EP3683320A3 (en) Mirna fingerprint in the diagnosis of lung cancer
WO2013033609A3 (en) Methods and compositions for the treatment and diagnosis of cancer
EP4219765A3 (en) Prostate cancer prognosis using biomarkers
EP2576837A4 (en) CIRCULATING NUCLEIC ACID BIOMARKERS ASSOCIATED WITH PROSTATE CANCER
TN2013000464A1 (en) Biomarkers for hedgehog inhibitor therapy
DE602006002809D1 (de) Verfahren zur erkennung eines ovarialkarzinoms
MX368394B (es) Receptor alfa de folato como marcador de diagnostico y pronostico para canceres que expresan receptor alfa de folato.
WO2008097908A3 (en) Methods of diagnosing and prognosing lung cancer
EA030186B9 (ru) Способ проведения количественных анализов
NZ629074A (en) Biomarkers for gastric cancer and uses thereof
WO2012096545A3 (ko) 췌장암 암줄기세포 특성을 이용한 췌장암 신규 바이오마커 및 그의 용도
WO2011021041A3 (en) Survival prognostic assay
HK1149956A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
WO2012178188A3 (en) Molecular diagnostic panel of eosinophilic gastrointestinal disorders
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
WO2010009074A3 (en) Method for predicting and detecting tumor metastasis
WO2015095862A3 (en) Microrna biomarkers for ovarian cancer